RELATIONSHIP BETWEEN CLINICAL FEATURES OF MYELODYSPLASTIC SYNDROME AND ITS CLASSIFICATION, DIAGNOSIS AND PROGRESSION, AND PATIENT PROGNOSIS

Jing Liu^#, Rui Shi^#, Jing Wang, Ying Guo, Zhongjing Han, Rongyan Guan, Yun Li^*

Department of hematology, Daqing oil-field general hospital, Daqing 163000, China

Objective: To analyze the relationship between the clinical features of myelodysplastic syndrome (MDS) and the classification, diagnosis and progression, and patient prognosis of MDS. 

Methods: A total of 169 patients with MDS admitted to our hospital from January 2019 to January 2020 were enrolled and divided into four groups: refractory hemocytopenia with monolineal dysplasia (rcud) (n=28), cricoid iron granulocytic refractory anemia (RARs) (n=10), refractory hemocytopenia with multilineage dysplasia (RCMD) (n=63), and refractory anemia with primitive cells (n=63). According to the Revised International Prognostic Scoring System (IPSS-R), the patients were also divided into low-risk (n=33), moderate-risk (n=57), high-risk (n=44), and extremely high-risk groups (n=35). The gender, age, and clinical manifestations of the patients were recorded and compared. The white blood cell (WBC), red blood cell (RBC), hemoglobin (HB), platelet (PLT), and neutrophil (NEU) counts; bone marrow; and chromosomes were examined and compared. 

Results: A total of 169 patients with MDS were included in this study, including 97 male patients (57.40%) and 72 female patients (42.60%). The average age of all patients was 56 years, and 44.38% of them were over 60 years old. The average WBC, RBC, HB, PLT, and NEU counts, were 3.76×10⁹/L, 2.24×10¹²/L, 70.56 g/L, 78.61×10⁹/L, and 1.69×10⁹/L, respectively. The detection rate of chromosomal abnormalities was 38.46%. Of these, complex chromosome abnormalities accounted for 9.47%, and noncomplex chromosome abnormalities accounted for 28.99%. There was no significant difference in age; WBC, RBC, HB, PLT, or NEU count; myeloproliferative activity; or chromosomal abnormalities in patients with MSD (P>0.05). There were significant differences in WBC, RBC, HB, PLT, and NEU count; myeloproliferative activity; and chromosomal abnormalities in the different disease progression and prognosis groups (P<0.05). There was no significant difference in the age of patients in the different disease progression and prognosis groups (P>0.05). 

Conclusion: MDS is a group of heterogeneous clonal cell diseases that are often seen in elderly individuals. Anemia, hemorrhage, and infection are the main reasons that patients with MDS seek medical attention. It is of great significance to improve the clinical data, bone marrow examination, and chromosomal abnormality examination of patients with MDS for clear diagnosis, typing, and prognosis evaluation.